Contents
Academic literature on the topic 'Varizes esofágicas e gástricas'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Varizes esofágicas e gástricas.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Varizes esofágicas e gástricas"
Bem, Ricardo Schmitt de, Fabiana Lígia Lora, Raquel Canzi Almada de Souza, Marcus Adriano Trippia, Heda M. B. Amarante, and Eliane R. Carmes. "Correlação das características do ecodoppler do sistema porta com presença de alterações endoscópicas secundárias à hipertensão porta em pacientes com cirrose hepática." Arquivos de Gastroenterologia 43, no. 3 (September 2006): 178–83. http://dx.doi.org/10.1590/s0004-28032006000300005.
Full textPetroianu, Andy. "Tratamento cirúrgico da hipertensão porta na esquistossomose mansoni." Revista da Sociedade Brasileira de Medicina Tropical 36, no. 2 (April 2003): 253–65. http://dx.doi.org/10.1590/s0037-86822003000200010.
Full textBatista-Neto, João, Luciano Becker Tognetti, Laércio Tenório Ribeiro, Maria do Carmo Balwani, Tadeu Muritiba, and Elton Elton Correa Alves. "Perfil evolutivo das varizes esofágicas pós esplenectomia associada à ligadura da veia gástrica esquerda e escleroterapia na hipertensão portal esquistossomótica." ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) 26, no. 1 (March 2013): 49–53. http://dx.doi.org/10.1590/s0102-67202013000100011.
Full textAntunes, Raquel Aparecida, and Ivana Duval-Araujo. "Evolução das varizes esofagogástricas após anastomose esplenorrenal proximal versus esplenorrenal distal." Revista do Colégio Brasileiro de Cirurgiões 27, no. 2 (April 2000): 101–5. http://dx.doi.org/10.1590/s0100-69912000000200007.
Full textÉboli, Lígia Patrícia E. Carvalho Batista, Maria Carolina Amando do Nascimento Matias, Raquel Nogueira Cordeiro, Gabriela Maria Carvalho Araújo, Emanuel Alexandre Amando Souza, and Diego Laurentino Lima. "Avaliação da média de ressangramento em pacientes pediátricos com trombose da veia porta que fizeram uso de profilaxia endoscópica e/ou medicamentosa." Revista de Medicina 97, no. 4 (December 17, 2018): 396–401. http://dx.doi.org/10.11606/issn.1679-9836.v97i4p396-401.
Full textAssef, José Cesar, Sérgio San Gregório Fávero, Luiz Arnaldo Szutan, and Armando de Capua Júnior. "Recidiva hemorrágica em pacientes esquistossomóticos operados." Revista do Colégio Brasileiro de Cirurgiões 25, no. 4 (August 1998): 265–70. http://dx.doi.org/10.1590/s0100-69911998000400009.
Full textMaluf-Filho, Fauze, Carlos Marcelo Dotti, Alberto Queiroz Farias, Carlos Kupski, Dalton Marques Chaves, Everson Artifon, Frank Nakao, et al. "I Consenso Brasileiro de Ecoendoscopia." Arquivos de Gastroenterologia 44, no. 4 (December 2007): 353–58. http://dx.doi.org/10.1590/s0004-28032007000400014.
Full textUmanzor, Sarai Elizabeth, Kristell Patricia Hawith, and Ruth Maricela Banegas. "Sangrado Digestivo en Niños: Hallazgos Endoscópicos." Acta Pediátrica Hondureña 7, no. 1 (January 11, 2019): 561–66. http://dx.doi.org/10.5377/pediatrica.v7i1.6934.
Full textKoyama, Francisco Susumu Corrêa, Kiyoshi Hashiba, Sansom Henrique Bromberg, and Carlos Alberto Cappelanes. "Tratamento endoscópico das varizes esofágicas utilizando alças pré-atadas confeccionadas com fio de poliamida." Arquivos de Gastroenterologia 43, no. 4 (December 2006): 328–33. http://dx.doi.org/10.1590/s0004-28032006000400016.
Full textAssef, José Cesar, Adriana Christina Pozzobon de Oliveira Vieira, Hellen Christina Garcia Saito, Carmen Lúcia Penteado Lancellotte, Luiz Arnaldo Szutan, and Armando De Capua Junior. "Modelo experimental de formação de varizes esofágicas por hipertensão portal esquistossomótica em hamsters." Revista do Colégio Brasileiro de Cirurgiões 32, no. 4 (August 2005): 209–13. http://dx.doi.org/10.1590/s0100-69912005000400011.
Full textDissertations / Theses on the topic "Varizes esofágicas e gástricas"
Tafarel, Jean Rodrigo [UNIFESP]. "Avaliação dos escores MELD, Child-Turcotte-Pugh, APRI, contagem de plaquetas e testes hepáticos como indicadores da presença de varizes de esôfago com ou sem necessidade de profilaxia para sangramento." Universidade Federal de São Paulo (UNIFESP), 2010. http://repositorio.unifesp.br/handle/11600/9106.
Full textObjetivo: Determinar se o escore MELD (Model for end-stage liver disease), classificação de Child-Turcotte-Pugh (CTP), APRI (AST to platelet ratio index), testes hepáticos e contagem de plaquetas são preditores da presença de varizes esofágicas (VE) ou de VE com necessidade de profilaxia para sangramento varicoso (VNP). Métodos: Trezentos pacientes cirróticos (193 homens; média etária de 53,10 anos; hepatite C crônica como etiologia predominante da cirrose) foram analisados prospectivamente. Considerou-se como VE de fino calibre aquelas que desapareciam com a insuflação do órgão; médio calibre aquelas que ocupavam até 1/3 da luz esofágica e de grosso calibre aquelas que ocupavam mais do que 1/3 da luz. Varizes de médio e grosso calibre foram consideradas VNP. Realizaram-se análises uni e multivariada para estabelecer a relação entre a presença de varizes (qualquer calibre e VNP) e as características destes pacientes (MELD, classificação CTP, APRI, exames de bioquímica hepática e contagem de plaquetas). Resultados: Cento e setenta e um pacientes (57%) possuíam VE, dos quais 35% (n = 105) possuíam VNP. A distribuição das VE de acordo com a classificação de CTP foi: A, 49%; B, 75,30% e C, 80% (p < 0,01). Em análise univariada os preditores independentes da presença de VE foram: MELD > 8 (p = 0,02); APRI > 1,64 (p = 0,01); contagem plaquetária inferior a 93.000/mm3 (p < 0,01); AST > 1,34xLSN (p = 0,01) e bilirrubina total > 1mg/dl (p = 0,04). Escore MELD acima de 8 teve o maior valor discriminante para a presença de VE, com sensibilidade de 80,10% e especificidade de 51,20%. Fatores independentemente associados à VNP foram: trombocitopenia (< 92.000/mm3; p < 0,01) e AST > 1,47xLSN (p = 0,03). Contagem plaquetária < 92.000/mm3 possui sensibilidade de 65,70% e especificidade de 57,90% para a presença de VNP. Conclusões: Escore MELD elevado foi o melhor preditor isolado da presença de VE de qualquer calibre e plaquetopenia < 92.000/mm3, foi o melhor preditor para varizes com necessidade de profilaxia. No entanto, nenhum destes concilia altos valores de sensibilidade e especificidade.
Purpose: The aim of this study was to determine whether MELD, Child-Turcotte-Pugh (CTP) class, APRI and laboratory tests could predict the presence of EV or varices which need prophylactic therapy (EV with medium or large size). Methods: Three hundred cirrhotic patients (193 men; mean age 53,1 years; majority with cirrhosis from chronic C hepatitis) were prospective analyzed. Uni and multivariate analysis were used to evaluate associations between the presence of EV (any size and medium or large EV) and patients’ characteristics (MELD, CTP class, APRI, platelets count and liver tests). Small varices were regarded as those which flatten with insufflation; medium varices those which protruded less than 1/3 of the lumen and large ones those which protruded more than 1/3. Results: One hundred seventy one patients (57%) had EV, of whom 35% (105) had varices which need prophylactic therapy. The distribution of EV according to the CTP class was as follows: A, 49%; B, 75,3% and C, 80%. Independent predictors of the presence of EV were: MELD > 8 (p = 0,02); APRI > 1,64 (p = 0,01); a platelet count < 93.000/mm3 (p < 0,01); AST > 1,34xUNL (p = 0,01) and total bilirubin > 1 mg/dl (p = 0,04). MELD > 8 had the highest discriminative value for presence of EV with sensitivity of 80,1% and specificity of 51,2%. Factors independently associated with EV which need prophylactic therapy were: thrombocytopenia (< 92.000/mm3; p < 0,01) and AST > 1,47xUNL (p = 0,03). A platelet count < 92.000/mm3 had sensitivity of 65,7% and specificity of 57,9% for the presence of varices which need prophylactic therapy. Conclusions: High values on MELD are associated with EV and thrombocytopenia (< 92.000/mm3), with varices which need prophylactic therapy. Considering their low sensitivity and specificity, it is suggested to maintain the recommendation of upper gastrointestinal endoscopy for all cirrhotic patients.
TEDE
BV UNIFESP: Teses e dissertações
Adami, Marina Rossato. "Análise de métodos não invasivos preditores de varizes esofágicas em pacientes pediátricos com hipertensão portal." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2013. http://hdl.handle.net/10183/119408.
Full textIntroduction: The rupture of esophageal varices (EV) is a serious complication of portal hypertension (PH). The esophagogastroduodenoscopy (EGD) is the gold standard for diagnosis of EV and to define the bleeding risk. It is indicated in all adult patients with chronic liver disease, at the diagnosis of cirrhosis. In pediatrics, the timing of the EGD is not established. The search for non-invasive methods to diagnose the presence of EV and the risk of bleeding is an interesting topic. Studies involving children are scarce compared to those in the adult population. The aims of this study were to evaluate noninvasive parameters, for the diagnosis of EV in children and adolescents with PH and assess their ability to predict VE of medium and large caliber (F2F3). Methods: Retrospective cross-sectional study. Pediatric patients diagnosed with HP submitted to EGD for EV screening were included. The noninvasive parameters studied were those previously described in the literature and available on our institution. They were assessed individually or as scores and/or mathematical models (splenomegaly, esplenometry, spleen size z score, platelet count, platelet count / spleen size, platelet count / spleen size z score, Clinical Prediction Rule proposed by Gana et al (CPR), Risk Score, APRI test, classification and Child-Pugh score, MELD and PELD). Statistical analyses were conducted using SPSS version 18.0 and a p value < 0.05 was considered statistically significant. The cutoff points for each variable were defined based on ROC curve and the area under the curve (AUROC) results. Positive (PPV) and negative (NPV) predictive values, positive (PLR) and negative likelihood ratio (NLR) were calculated. A logistic regression model using the statistically significant variables were constructed in order to identify independent predictors of outcomes. The study was approved by the HCPA Research Ethics Committee (11-0635). Results: One hundred and three patients were included (age: 8.9 ± 4.7 years). Ninety-eight patients (95.2%) with intrahepatic PH and 5 (4.8%) with extrahepatic portal vein obstruction. EV were identified in 71 children (68.9%), including 68 patients with intrahepatic PH. Thirty-four patients had large EV (F2F3). The median time between blood sample collection and EGD was 15 days (6-40 days). In univariate analysis, spleen size, platelet count, CPR, Risk Score, APRI test and platelet count/ spleen size z score ratio reached statistical significance. At AUROC analyzes, platelet count, platelet count/ spleen size z score ratio, CPR and Risk Score were identified as the best predictors of EV. In logistic regression analyses, the presence of EV was considered as the dependent variable, corrected for albumin, bilirubin and z score spleen size. Children with CPR <114 were 20.7 times more likely to have EV. Risk Score> -1.2 increased the likelihood of EV presence in 7.47 times. Regarding the presence of large EV (F2F3), children who had CPR <114, the risk score> -1.2 and the relationship platelet count/spleen size z score ratio < 25 had a higher risk of this outcome. Conclusions: In pediatric patients with PH, platelet count, CPR and Risk Score were predictors of EV. CPR, Risk Score> -1.2 and the platelet count/spleen size z score ratio identified those with EV liable to endoscopic treatment.
Santos, Marcus Melo Martins dos [UNIFESP]. "Tratamento endoscópico de varizes esofágicas em pacientes cirróticos: ligadura elástica versus injeção de cianoacrilato." Universidade Federal de São Paulo (UNIFESP), 2008. http://repositorio.unifesp.br/handle/11600/23905.
Full textIntrodução: A hemorragia digestiva alta por ruptura de varizes esofágicas (VE) é uma das principais causas de morte em pacientes cirróticos com hipertensão portal, especialmente entre os cirróticos com grau avançado de disfunção hepática. Apesar de ser considerado o método de escolha para varizes de esôfago, os resultados da ligadura elástica (LE) em pacientes cirróticos em fase avançada da doença são piores. Por este motivo idealizamos um estudo comparando a injeção de cianoacrilato (IC) com LE nestes pacientes. Objetivos: Comparar LE à IC para tratamento de VE em pacientes cirróticos considerando: eficácia para erradicação, sangramento até a erradicação, complicações, bacteremia, mortalidade e recidiva das VE. Pacientes e método: Em um estudo prospectivo e randomizado, foram incluídos 38 pacientes cirróticos com índice de Child-Pugh ≥ 8 pontos, com VE de médio ou grosso calibre e sinais da cor vermelha, para tratamento das VE. Os pacientes foram divididos em 2 grupos: ligadura elástica (LE; n = 20) e injeção de cianoacrilato (IC; n = 18). A LE foi realizada com o dispositivo de ligadura múltipla reprocessável. A IC foi feita com 0,5 ml de cianoacrilato diluído em 0,5 ml de Lipiodol® nos vasos de médio ou grosso calibre, sendo os cordões finos tratados com escleroterapia. Foi realizada complementação com injeção de oleato de etanolamina a 2,5% em ambos os grupos quando necessário. Os pacientes foram acompanhados clínica e endoscopicamente por pelo menos 1 ano. Resultados: Os grupos foram semelhantes em relação a dados demográficos, etiologia da cirrose, grau de disfunção hepática, antecedente de sangramento por VE, uso de beta-bloqueadores, características das VE, presença de varizes gástricas e intensidade da gastropatia hipertensiva portal. No grupo LE, 90% tiveram VE erradicadas, com média de 3,17 sessões e 75,4 dias. No grupo IC, a erradicação foi 72%, com média de 3 sessões e 55,4 dias, sem diferença significante. Não houve diferença com relação ao sangramento até a erradicação (p = 0,170) e ao óbito causado pelo sangramento até a erradicação (p = 0,328). A mortalidade foi semelhante nos dois grupos, com 11 óbitos (55%) no grupo LE e 10 óbitos (56%) no grupo IC. A comparação das curvas de sobrevida dos dois grupos pelo teste de log-rank não mostrou diferença (p = 0,524). A idade foi o único fator de risco independente relacionado com a mortalidade (p = 0,009) após análise multivariada. Não houve diferença na taxa de complicações maiores nos dois grupos. Um paciente no grupo LE apresentou estenose esofágica, enquanto três no grupo IC tiveram complicações (sangramento por úlcera esofágica em dois e embolia do cianoacrilato com infarto esplênico em um paciente). Complicações menores foram mais freqüentes no grupo IC (72% x 20%, p = 0,008), principalmente dor retroesternal e disfagia (p = 0,0045). Não houve diferença quanto a incidência de bacteremia (p = 0,231). Os pacientes do grupo IC apresentaram um risco maior de recidiva das VE após análise das curvas de probabilidade livre de recidiva nos dois grupos (p = 0,041). O antecedente de hemorragia digestiva alta varicosa foi o único fator de risco independente relacionado com a recidiva de VE (p = 0,027) após análise multivariada. CONCLUSÃO: A LE e a IC tiveram eficácia semelhante em relação à erradicação das varizes esofágicas. A taxa de sangramento até a erradicação, complicações maiores, bacteremia e mortalidade foram semelhantes. No entanto, as complicações menores e a recidiva das varizes esofágicas foram maiores no grupo tratado com IC.
Introduction: Esophagic variceal bleeding is a major cause of death among cirrhotic patients. Although endoscopic variceal ligation (EVL) has been recommended to esophageal varices (EV) eradication, the result in patients with advanced hepatic dysfunction is limited. We planned a trial to compare CI and EVL in the treatment of esophageal varices in these patients. Aims: To compare EVL and CI in the treatment of EV in cirrhotic patients, considering: eradication of EV, bleeding episodes until eradication, minor and major complications, bacteremia, mortality and recurrence of EV. Patients and Methods: Thirty-eight cirrhotic patients with EV of medium or large caliber with red-spots and Child-Pugh index ≥ 8 were enrolled in the study. Patients were randomized into 2 groups, EVL (n = 20), in a three-week interval basis or CI (n = 18) with a mixture of 0.5 ml of cyanoacrylate and Lipiodol® (1:1) in a two week interval basis, with a second injection in each vessel if necessary. Small varices were treated with sclerotherapy. Radiographic control was made after CI. Results: There was no statistic difference between the groups regarding to etiology of cirrhosis, severity of hepatic dysfunction, history of previous variceal bleeding, β-blocker use or endoscopic findings. Effectiveness was similar in both groups, with a variceal eradication rate of 90% in EVL group and 72% in CI group. On average, 3.17 and 3 sessions were necessary, respectively. Bleeding episodes until eradication (p = 0.170) and mortality related to such episodes (p = 0.328) were equally observed in both groups. Also, overall mortality was similar in EVL and CI groups, 55% vs. 56% (log-rank test, p = 0.524). The only independent risk factor related to mortality (multivariate analysis) was the patient age (p = 0.009). Major complications were not statistically different in the two groups. In EVL group, one patient had esophageal stenosis. In the CI group, two patients had esophageal ulcer bleeding and one had splenic infarction after splenic artery embolization of cyanoacrylate. Minor complications were more frequent in group CI (p = 0.008), mainly due to severe transitory retroesternal pain and dysphagia. Bacteremia rates were similar in the two groups (p = 0.231). A higher risk of variceal recurrence was observed in CI group (log-rank test, p = 0.041). The only independent risk factor related to variceal recurrence (multivariate analysis) was a positive history of variceal bleeding (p = 0.027). Conclusions: There were no significant difference between EBL and CI regarding to effectiveness, mortality, and major complications in esophageal varices management of cirrhotic patients with severe liver dysfunction. Minor complications and variceal recurrence were significantly more common in CI group.
BV UNIFESP: Teses e dissertações
Dias, Juliana Tedesco. "Varizes de esôfago nas crianças podem ser previstas sem a realização de endoscopia digestiva alta?" Botucatu, 2017. http://hdl.handle.net/11449/152443.
Full textResumo: Introdução: Varizes esofágicas (VE) são uma consequência da hipertensão portal (HP) que pode levar os pacientes à morte quando há sua ruptura. O uso rotineiro de endoscopia digestiva alta (EDA) visa diagnosticá-las precocemente e tratá-las como profilaxia de sangramento. O estabelecimento de índices preditivos não invasivos de varizes esofágicas busca identificar através de variáveis não invasivas os pacientes com maior probabilidade de possuir varizes que requeiram tratamento endoscópico, evitando assim o procedimento naqueles com baixa probabilidade destas. Objetivos: avaliar a acurácia de testes preditivos não invasivos, comparados à EDA, para o diagnóstico de varizes esofágicas em crianças e adolescentes com hipertensão portal, avaliar o seguimento dos pacientes que tiveram diagnóstico de variz tratável (F2 e F3) mediante intervenção com ligadura elástica em 3 endoscopias sucessivas, a evolução da gastropatia hipertensiva e erradicação de varizes esofágicas nestes pacientes. Métodos: Estudo prospectivo, unicêntrico, em pacientes com HP, acompanhados no ambulatório de Hepatologia Pediátrica e no Setor de Endoscopia Pediátrica do Hospital das Clínicas da Faculdade de Medicina de Botucatu–Unesp no período de 2014 a 2017.Foram avaliadas as variáveis: contagem de plaquetas, albumina, escore Z do maior diâmetro do baço, APRI, P/SSAZ e CPR. Valores de p<0,05 foram considerados estatisticamente significativos. Sensibilidade e especificidade foram calculados baseando-se nos pontos... (Resumo completo, clicar acesso eletrônico abaixo)
Doutor
Lima, Talles Bazeia. "Segurança do risedronato na cirrose hepática análise endoscópica de pacientes com varizes esofágicas em tratamento de osteoporose /." Universidade Estadual Paulista (UNESP), 2018. http://hdl.handle.net/11449/153765.
Full textApproved for entry into archive by ROSANGELA APARECIDA LOBO null (rosangelalobo@btu.unesp.br) on 2018-04-26T17:26:01Z (GMT) No. of bitstreams: 1 lima_tb_dr_bot.pdf: 14703661 bytes, checksum: c158c5e515319db12071983670b54172 (MD5)
Made available in DSpace on 2018-04-26T17:26:01Z (GMT). No. of bitstreams: 1 lima_tb_dr_bot.pdf: 14703661 bytes, checksum: c158c5e515319db12071983670b54172 (MD5) Previous issue date: 2018-02-28
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
A osteoporose é uma complicação frequente da cirrose hepática (CH) que pode levar a fraturas, comprometendo a qualidade e a expectativa de vida. Bisfosfonatos são frequentemente utilizados para reduzir o risco de fraturas por osteoporose, mas podem provocar danos à mucosa gastrointestinal. O objetivo deste estudo foi avaliar a segurança do risedronato em pacientes com CH e varizes de esôfago (VE). De 354 pacientes com CH, 164 foram considerados elegíveis e alocados de acordo com a densidade mineral óssea após densitometria. No grupo intervenção, 52 indivíduos com osteoporose receberam tratamento com risedronato oral (35 mg / semana), suplementação de cálcio e vitamina D. No grupo controle, 51 indivíduos com osteopenia receberam apenas suplementação de cálcio e vitamina D. Todos foram submetidos a endoscopias de vigilância durante 1 ano e à densitometria ao final do estudo. A média etária e a proporção de mulheres foi maior no grupo intervenção. O MELD (Model of End-Stage Liver Disease) no grupo intervenção e controle foi 9,6 (5,9-15,5) e 10,3 (6,5-19), respectivamente (p= 0,047). O grupo controle teve mais casos de doença hepática alcoólica (p< 0,001). Em ambos os grupo a maioria dos indivíduos tinha classificação Child-Pugh A e VE de baixo risco de sangramento. Não houve diferença entre os grupos quanto aos achados endoscópicos observados durante a intervenção. Não houve hemorragia digestiva alta no grupo intervenção, mas em 2 casos do grupo controle. O grupo intervenção foi o único em que houve ganho de massa óssea (coluna lombar): média do T score -3,2 e -2,7 pré e pós-tratamento, respectivamente (p= 0,001). Porém houve mais casos de artralgia e mialgia nesse grupo (p= 0,031 e 0,006), respectivamente. Esses resultados, de efeito prático imediato, sugerem que o risedronato é seguro na CH compensada com VE de baixo risco de sangramento sob vigilância endoscópica.
Osteoporosis is a common complication of liver cirrhosis that can lead to fractures, compromising quality of life and survival rate. Bisphosphonates are often used to reduce the risk of fractures caused by osteoporosis, but can lead to digestive mucosal damage. The aim of this study was to evaluate the safety of risedronate for patients with cirrhosis and esophageal varices. Of the 354 cirrhotic patients invited to participate, 164 were considered eligible and allocated according to the bone mineral density after densitometry. In the intervention group, 52 individuals with osteoporosis received oral risedronate 35 mg weekly plus calcium and vitamin D supplementation. In the control group, 51 individuals with osteopenia received only calcium and vitamin D supplementation. All the subjects underwent surveillance endoscopies within 1 year and another bone densitometry at the end of the trial. The mean age and the proportion of women were higher in the intervention group. The Model of End-Stage Liver Disease (MELD) scores in the intervention and control group were 9.6 (5.9-15.5) and 10.3 (6.5-19), respectively (p= 0.047). The control group had more subjects with alcoholic liver disease (p< 0.001). In both groups the majority of the individuals had Child-Pugh A classification and low-risk bleeding esophageal varices. There was no difference between the groups regarding esdoscopic findings during the intervention. There was no upper gastrointestinal bleeding in the intervention group but 2 in the control group. The intervention group was the only one that achieved increase in bone density (lumbar spine): Mean T score -3,2 and -2,7 pre and post treatment, respectively (p= 0,001). However, arthralgia and myalgia were more frequent in this group (p= 0.031 and 0.006 respectively). The results, which are of immediate practical effect, suggest that risedronate is safe in compensated liver cirrhosis with low-risk bleeding esophageal varices under endoscopic surveillance and allowed a gain of bone mass.
FAPESP: 2016/07117-9
MACÊDO, Liana Gonçalves de. "Síndrome hepatopulmonar em pacientes com hipertensão portal e varizes esofágicas por esquistossomose mansônica e doença hepática crônica mista." Universidade Federal de Pernambuco, 2013. https://repositorio.ufpe.br/handle/123456789/11710.
Full textMade available in DSpace on 2015-03-10T17:47:45Z (GMT). No. of bitstreams: 2 Tese LIANA GONÇALVES DE MACEDO.pdf: 1255558 bytes, checksum: 0856d0f5444800d341169b03abd90e4b (MD5) license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) Previous issue date: 2013-09-27
A síndrome hepatopulmonar representa uma grave complicação da doença hepática ou hipertensão portal e confere pior prognóstico aos pacientes cirróticos candidatos ao transplante de fígado, que têm este procedimento como única possibilidade de cura. Esta tese teve como objetivo verificar a ocorrência da síndrome hepatopulmonar em pacientes com hipertensão portal. Para tanto, foram selecionados os pacientes atendidos nos ambulatórios de Esquistossomose e de Hepatologia do Hospital das Clínicas da Universidade Federal de Pernambuco, no período de abril de 2010 a junho de 2012. Os resultados do estudo são apresentados no formato de dois artigos. O ARTIGO 1 (Ocorrência de síndrome hepatopulmonar em pacientes com hipertensão portal e varizes esofágicas com e sem cirrose: estudo de corte transversal) descreve um estudo de corte seccional com comparação entre os grupos com e sem síndrome hepatopulmonar. De um total de 1.475 pacientes avaliados, incluíram-se 129 com hipertensão portal e varizes esofágicas por esquistossomose hepatoesplênica e doença hepática crônica mista. A média de idade foi de 56 anos e 56% eram do sexo masculino. A ocorrência da síndrome hepatopulmonar foi de 35,7% (95% de Intervalo de Confiança [IC]: 27,3 – 44,0) e foi mais frequente naqueles com aranhas vasculares (Odds Ratio [OR]: 2,86; IC: 1,20-6,82; p = 0,018) e com Child-Pugh B/C (OR: 2,99; CI: 1,36-6,58; p = 0,007) e se associou à menor média de albumina (p = 0,006), maior média de bilirrubina total (p = 0,020), bilirrubina direta (p = 0,025) e do MELD (p = 0,007). Em relação à causa da hipertensão portal, a síndrome hepatopulmonar foi mais frequente nos pacientes com doença hepática mista (42,6%) quando comparada àqueles com esquistossomose hepatoesplênica pura (27,9%). No modelo multivariado final permaneceram associados à síndrome hepatopulmonar a idade, aranhas vasculares e bilirrubina direta. Em conclusão, a ocorrência da síndrome hepatopulmonar foi elevada neste estudo que envolveu pacientes com hipertensão portal, sendo mais frequente naqueles com maior grau de comprometimento da função hepática. O ARTIGO 2 (Síndrome hepatopulmonar na hipertensão portal não cirrótica por esquistossomose hepatoesplênica: uma série prospectiva), descreve uma série de casos na qual avaliaram-se 61 pacientes com hipertensão portal por esquistossomose hepatoesplênica e varizes esofágicas, com média de idade de idade de 55 anos, sendo 67% do sexo feminino. O sangramento digestivo prévio ocorreu em 59% dos pacientes. A ocorrência da síndrome hepatopulmonar foi de 28% (IC: 16,3 - 39,4) sendo mais frequente nos pacientes com fibrose periportal padrão D (29,4%) quando comparado ao padrão E/F (27,3%) e os pacientes com a síndrome hepatopulmonar apresentaram maior diâmetro de veia porta e esplênica quando comparados àqueles sem a síndrome, mas sem diferenças significativas. A síndrome hepatopulmonar se associou à maior média de bilirrubina total (p = 0,047), bilirrubina direta (p = 0,031) e de INR (p = 0,021). Em conclusão, a ocorrência da síndrome hepatopulmonar foi elevada nesta série, possivelmente pelos níveis elevados de hipertensão portal e foi mais frequente naqueles que apresentavam indícios de comprometimento da função hepática, provavelmente consequente à ocorrência de sangramentos digestivos.
Ramos, Danusa de Souza. "Elastografia hepatoesplênica para predizer varizes esofágicas em pacientes com hipertensão portal não cirrótica: estudo de acurácia diagnóstica." Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/5/5168/tde-07112018-114450/.
Full textBackground and rationale: transient elastography is a noninvasive, validated, method allowing evaluation of liver fibrosis by measurement of liver stiffness and under investigation to predict the presence of esophageal varices. However, elastography has been validated only in diseases that progress to cirrhosis. In a literature review we found few studies on diagnostic accuracy in patients with non-cirrhotic portal hypertension. Aims: to evaluate the accuracy of hepatosplenic elastography (FibroScan and ARFI) to predict the presence of esophageal varices and whether varices are at risk of bleeding in patients with non-cirrhotic portal hypertension. To evaluate the concordances of the two techniques and correlate them with other indexes such as the platelet /spleen diameter ratio, APRI and FIB-4. Methods: patients with confirmed diagnosis of the following conditions were included: extrahepatic portal vein occlusion, schistosomiasis, idiopathic non-cirrhotic portal hypertension and congenital hepatic fibrosis. Upper digestive endoscopy was considered as a marker of the presence of clinically significant portal hypertension. Inclusion criteria: age above one year; defined etiological diagnosis; agreement of the patient or legal guardian to participate in the study. Exclusion criteria: cirrhosis confirmed by combination of clinical, imaging and laboratory diagnostic criteria or by liver biopsy when the result was available; post sinusoidal portal hypertension; conditions that technically preclude the performance of elastography (massive ascites and heart failure); splenectomy; pregnancy; advanced hepatocellular carcinoma. The study design was prospective, transversal, according to the STARD methodology, evaluating the accuracy, sensitivity, specificity, positive and negative predictive values and positive and negative likelihood ratios. The procedures of the study were: review of medical records data, abdominal ultrasonography and hepatosplenic elastography with FibroScan and ARFI equipment / methods. Cut-off points for elastography were determined by ROC curves. Results: liver stiffness measurement by FibroScan were 5.91 ± 1.87 kPa in extrahepatic portal vein occlusion, 8.89 ± 3.96 kPa in schistosomiasis, 10.60 ± 3.89 kPa in portal hypertension non-cirrhotic idiopathic and 10.30 ± 4.14 kPa in congenital hepatic fibrosis, whereas by ARFI were 1.27 ± 0.23 m/s; 1.35 ± 0.45 m/s; 1.43 ± 0.40 m/s; 1.55 ± 0.39 m/s; respectively. Spleen stiffness measurement by FibroScan were 60.82 ± 20.56 kPa in extrahepatic portal vein occlusion, 54.16 ± 22.94 kPa in schistosomiasis, 52.64 ± 21.97 kPa in idiopathic non-cirrhotic portal hypertension, and 48.50 ± 24.86 kPa in congenital hepatic fibrosis, while by ARFI were 3.22 ± 0.62 m/s; 3.01 ± 0.74 m/s; 2.86 ± 0.53 m/s; 2.80 ± 0.55 m/s; respectively. Liver stiffness measurement by FibroScan with a cut-off of 65.1 kPa had an accuracy of 0.62 (95%confidence interval, 0.46-0.78, p=0.121) for the presence of esophageal varices. The best cut-off point for predicting the presence of varices at high risk of bleeding was 40.05 kPa (accuracy, 0.63, 95% confidence interval, 0.52-0.76, p = 0.016). The spleen stiffness measurement by ARFI with a cut-off of 2.67 m/s showed (accuracy, 0.64, 95% confidence interval, 0.50-0.78, p=0.065) for the presence of esophageal varices. The best cut-off point for predicting the presence of varices at high risk of bleeding was 3.17 m/s (accuracy, 0.61, 95% confidence interval, 0.51-0.71, p=0.033) for varices at high risk of bleeding. Conclusions: spleen stiffness measurement by transient elastography (FibroScan and ARFI) presented a moderate accuracy and a high positive predictive value to diagnose the presence of esophageal varices. Spleen stifness by FibroScan when associated with platelet/spleen diameter ratio, there is a moderate accuracy with a high specificity to predict varices at high risk of bleeding. However, overlapping values between patients with or without varices was high and this precludes the clinical applicability of these methods
Carneiro, Fred Olavo Aragão Andrade. "Fatores preditivos ecoendoscópicos da recidiva de varizes esofágicas após erradicação com ligadura elástica em pacientes com doença hepática crônica avançada." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/5/5168/tde-10032017-102256/.
Full textINTRODUCTION: Variceal recurrence after endoscopic band ligation for secondary prophylaxis is a frequent event. Some studies have reported a correlation between variceal recurrence and variceal re-bleeding with the endoscopic ultrasound (EUS) features of para-esophageal vessels. OBJECTIVE: A prospective observational study was conducted to correlate EUS evaluation of para-esophageal varices, azygos vein and thoracic duct with variceal recurrence after endoscopic band ligation variceal eradication in patients with in advanced chronic hepatic disease. METHODS: EUS was performed before and 1 month after endoscopic band ligation variceal eradication. Para-esophageal varices, azygos vein and thoracic duct maximum diameters were evaluated in pre-determined anatomic stations. After endoscopic band ligation variceal eradication, patients were submitted to endoscopic examinations every 3 months for 1 year. We looked for EUS features that could predict variceal recurrence. RESULTS: A total of 30 patients completed 1-year endoscopic follow-up. Seventeen (57%) patients presented variceal recurrence. There was no correlation between azygos vein and thoracic duct diameters with variceal recurrence. The maximum diameter of para-esophageal varices predicted variceal recurrence in both evaluation periods. Para-esophageal varices diameters that best correlated with variceal recurrence were 6.3 mm before endoscopic band ligation (52.9% sensitivity, 92.3% specificity, and 0.749 area under ROC curve); and 4 mm after endoscopic band ligation (70.6% sensitivity, 84.6% specificity, and 0.801 area under ROC curve). CONCLUSION: We conclude that paraesophageal varices diameter measured by EUS predicts variceal recurrence within one year after endoscopic band ligation variceal eradication. Paraesophageal diameter after variceal eradication is a better recurrence predictor, because it has lower cut-off parameter, higher sensitivity and higher area under the ROC curve
Rocha, Evandra Cristina Vieira da. "Influência dos parâmetros da coagulação no sangramento após ligadura elástica de varizes esofagianas em pacientes cirróticos." Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/5/5147/tde-15062011-105643/.
Full textBACKGROUND & AIMS. There is controversy over whether coagulation status predicts bleeding caused by ulceration after esophageal varices band ligation (EVL). METHODS: EVL was performed for primary (n=45) or secondary (n=105) prophylaxis in 150 patients with cirrhosis (Child A, n=74 [49%]; Child B, n=42 [28%]; Child C, n=34 [23%]). International Normalized Ratio (INR) and platelet counts (PC) were assessed in all. In 92 patients, levels of factor V, fibrinogen, D-dimer, protein C and protein S, von Willebrand factor and thromboelastography (TEG) were assessed. PC <50x103/mm3 and INR >1.5 were considered high-risk cutoffs for bleeding. Conversely, PC 50x103/mm3 with INR 1.5 were safe cutoffs. RESULTS: Overall, 11 patients (7.3%) had post-EVL ulcer bleeding. Bleeding occurred in 5 patients with Child A/B (4.3%) and 6 patients with Child C (17%) (p=0.0174 for Child A/B versus Child C). Eight patients with bleeding were among the 110 below the cutoff for INR and PC, whereas only 3 of the patients with bleeding were among the 40 patients with purported high-risk values (p=1.0). Among the 92 patients with expanded coagulation tests, bleeding occurred in 5. There was no difference in any of the coagulation parameters, including overall TEG patterns, between patients who did and did not bleed. CONCLUSION: Post-EVL ulcer bleeding was associated with Child C status but not with conventional or expanded coagulation indices in cirrhotic patients without renal failure or infection undergoing elective EVL. These results call into question the common use of prophylactic procoagulants in the elective setting. common use of prophylactic procoagulants in the elective setting
Makdissi, Fabio Ferrari. "Resultados a longo prazo da desconexão ázigo-portal e esplenectomia em portadores de esquistossomose hepato-esplênica: avaliação clínica, laboratorial, endoscópica e ultra-sonográfica com tempo de seguimento mínimo de 5 anos." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5154/tde-08122009-171703/.
Full textEsophagogastric devascularization and splenectomy (EGDS) is nowadays the most performed operation for esophageal varices bleeding recurrence prophylaxis in hepatosplenic schistosomiasis. Lower rebleeding rates are obtained through the association of EGDS with postoperative endoscopic sclerotherapy or elastic bandage of esophageal varices, however, there is a lack of studies showing long term results. The objectives of this study were to evaluate retrospectively EGDS results in patients with at least five years of follow-up. Clinical, laboratorial, endoscopic and ultrasonographic data of 97 patients submitted to EGDS from March 1989 to March 2001 were analyzed. The mean follow-up was 116.4 months. There was no postoperative clinical or laboratorial hepatic insufficiency. In the late follow-up we observed normalization of preexisting anemia, leucopenia, thrombocytopenia, hyperbilirubinemia, and a prothrombin activity time increase. There was a significant esophageal varices caliber and number reduction, cherry red spots signs and gastric varices decrease. Congestive gastropathy was observed more frequently but without clinical importance. Bleeding recurrence occurred in 24.7% of the patients, however, in 14.6% when esophageal varices hemorrhage was considered. Estimated probability of rebleeding prophylaxis over 20 years is 67.1% and 82.5% when variceal recurrence was considered. Bleeding recurrence occurred in four patients even after endoscopic evaluation showing esophageal varices eradication. There was a significant portal vein caliber reduction on late ultrasound assessment, compared to preoperative. We concluded that the EGDS with postoperative endoscopic treatment leads to good clinical results with low morbidity and mortality; provides laboratorial liver function improve and xx hypersplenism correction; determines endoscopic predictive signs of portal hypertension digestive bleeding decrease (large esophageal varices, cherry red spots signs and gastric varices), however congestive gastropathy is more frequent; allows appropriate bleeding prophylaxis in 67% of the patients over 20 years. Variceal hemorrhagic recurrence may occur even when esophageal varices eradication is reached suggesting the need of an endoscopic surveillance even in this group of patients.